Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma
S Wu, P Blombery, D Westerman, CS Tam - Current Treatment Options in …, 2023 - Springer
Opinion statement Mantle cell lymphoma (MCL) treatment advances have significantly
improved disease-free remission, with greater focus in clinical trials being placed on …
improved disease-free remission, with greater focus in clinical trials being placed on …
Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable
J Cartagena, A Deshpande, A Rosenthal… - Current Oncology …, 2024 - Springer
This paper concludes that MRD detection has prognostic value in MCL but faces limitations
in sensitivity and specificity. Further research is needed to establish the significance of low …
in sensitivity and specificity. Further research is needed to establish the significance of low …
Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR
JM Heger, Y d'Hargues, F Kleinert… - European journal of …, 2024 - Wiley Online Library
Although several promising approaches for the treatment of relapsed/refractory diffuse large
B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients …
B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients …